Printer Friendly

Zeria, Kyowa Hakko in Japan Co-development and Co-marketing Agreement for Asacol(R) for Inflammatory Bowel Disease.

Tokyo, Japan, Feb 8, 2007 - (JCN) - Zeria and Kyowa Hakko Kogyo Co., Ltd. concluded an agreement on January 29 for the co-development and co-marketing of Asacol - development code Z-206, generic name mesalazine, Asacol is an oral enteric-coated pharmaceutical formulation of mesalazine, a drug for inflammatory bowel disease (IBD).

Asacol was exclusively licensed in 2004 from Tillotts Pharma AG in Switzerland to Zeria, and the clinical Phase III trials are underway.

With this agreement, clinical development for ulcerative colitis is performed by Zeria alone but that for Crohn's disease will be conducted jointly.

After a marketing approval, Zeria will perform blistering and packaging, and supply to both companies for co-marketing the product.

Distribution, marketing and activities of providing, gathering and transmitting medical information will be conducted in parallel - 1 brand, 2 channels.

Copyright [c] 2007 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2007 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Feb 23, 2007
Words:141
Previous Article:Eizo Nanao to Acquire Tech Source, Enter Air Traffic Control Industry.
Next Article:Toray to Boost Carbon Fiber Production by 4,000 Tons in Japan, U.S. and France.
Topics:


Related Articles
Kyowa Hakko Kogyo, Mitsubishi Pharma Obtain Additional Approval for Recombinant Alteplase Agents.
Kyowa Hakko Kogyo to Release Plant-derived Glucosamine for Commercial Use in September.
Kyowa Hakko Kogyo Licenses Anti-tumor Drug Candidate Mitotic Kinesin Eg5 Inhibitor to Eli Lilly.
Kyowa Hakko Kogyo to Introduce Self-Injectable Drug for Treating Parkinson's Disease from Britannia Pharmaceuticals.
Kyowa Hakko Kogyo Completes Overseas Phase III Clinical Trials for KW-6002, Anti-Parkinson's Disease Agent.
Kyowa Hakko Kogyo to Expand Its Fuji Plant and Accelerate R&D for Antibody Drugs.
Alcon Japan, Kyowa Hakko Kogyo to Join Hands in Sales and Promotion of Olopatadine Hydrochloride Ophthalmic Solution.
Kyowa Hakko Develops World's First Fermentation-based Commercial Production Method for L-Tyrosine.
Kyowa Hakko Licenses Anticancer Agent KW-2401 to Keryx Biopharmaceuticals.
ARQULE/KYOWA HAKKO KOGYO SIGN ARQ 197 ASIA LICENSE.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters